{"id":"NCT00656136","sponsor":"Boehringer Ingelheim","briefTitle":"BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)","officialTitle":"Phase IIb/III Randomized, Double-blind Trial of BIBW 2992 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-Lung 1)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2013-10","completion":"2013-10","firstPosted":"2008-04-10","resultsPosted":"2013-11-27","lastUpdate":"2016-07-26"},"enrollment":585,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":[{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"BIBW 2992","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"BIBW 2992","type":"EXPERIMENTAL"}],"summary":"This randomized, double-blind, multi-center Phase IIb/III trial will be performed in patients with NSCLC who have received previous treatment with at least one but not more than two lines of cytotoxic chemotherapy (one line must have been a platinum-containing regimen) and either gefitinib or erlotinib for a period of at least 12 weeks and then progressed.\n\nThe primary objective of this randomized trial is to determine the efficacy of BIBW 2992 as a single agent (Arm A) as compared to a matching placebo (Arm B) in this patient population. Patients on both treatment arms will receive best supportive care in addition to study treatment.\n\nPatients enrolled into the trial will be treated and followed until death or lost to follow-up.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"From randomization until death or the last patient out date, an average of 12 months","effectByArm":[{"arm":"Placebo Plus Best Supportive Care (BSC)","deltaMin":11.96,"sd":null},{"arm":"Afatinib 50 mg/Day Plus Best Supportive Care (BSC)","deltaMin":10.78,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.7428"},{"comp":"OG000 vs OG001","p":"0.3955"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":90,"countries":["United States","Belgium","Canada","China","France","Germany","Hong Kong","Italy","Netherlands","Singapore","South Korea","Spain","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":["22452896"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":195},"commonTop":["Diarrhoea","Rash","Decreased appetite","Paronychia","Nausea"]}}